Positions

Professor of Medicine in the School of Medicine

2017 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2016 School of Medicine

Education

M.D., University of Virginia, School of Medicine 1995

1995 University of Virginia, School of Medicine

Internal Medicine Residency, University of Michigan, Ann Arbor 1995 - 1998

1998 University of Michigan, Ann Arbor

Hematology/Oncology Fellowship, University of North Carolina, Chapel Hill, School of Medicine 1998 - 2001

2001 University of North Carolina, Chapel Hill, School of Medicine

Clinical Trials

Nuvalent Alkazar-NVL-655 vs Alectinib 1st line treatment for ALK+ Non-Small Cell Lung cancer

Publications, Grants & Awards

• Grants (27)
• Academics Articles (2)

Showing 1 - 5 of 27

Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

2025-2030Nuvalent, Inc.

BI1479-0001

2023-2028Boehringer Ingelheim Pharmaceuticals, Inc.

Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655

2023-2027Nuvalent, Inc.

Methods to improve efficiency and robustness of clinical trials using information from real-world data with hidden bias

2023-2026Food and Drug Administration

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 Tumor Proportion Score.

2021-2026Mirati Therapeutics, Inc.

DCI Centers, Cancer Types & Labs

Thoracic Cancer